Abstract
Tocilizumab is used for treating moderate-severe Covid-19 pneumonia by targeting IL-6 receptors (IL-6R) and reducing cytokine release, but the pooled rate ratio among diabetic patients with adverse vs those with the more favorable course was 2.26. To date, the hyperglycemia has been shown to increase IL-6 and IL-6R, which has been suggested as a severity predictor in lung diseases of Covid-19 patients. However, there are no data about the effects of tocilizumab therapy on outcomes of hyperglycemic Covid-19 patients with pneumonia. To investigate this unsolved need, 475 Covid-19 positive patients were retrospectively studied since March 1st, 2020. Among them, 78 patients with pneumonia disease and treated with tocilizumab were further evaluated for a severe outcome (encompassing both the use of mechanical ventilation and/or death). Thirty-one (39.7%) hyperglycemic and 47 (60.3%) normoglycemic Covid-19 positive patients (blood glucose levels >140 mg/dl, at admission and/or during hospital stay) were evaluated. Noteworthy, 20 (64%) of hyperglycemic and 11 (23.4%) of normoglycemic patients were also diabetics (P<0.01). At admission, more elevated IL-6 levels in hyperglycemic patients were found and persists even after Tocilizumab administration. In a risk adjusted Cox-regression analysis, Tocilizumab in hyperglycemic did not attenuate the risks of severe outcome as did in normoglycemic patients (p<0.009). Therefore, we could conclude that reduced effects of Tocilizumab in hyperglycemic patients may due to the higher plasma IL-6 levels. Interestingly, when we added IL-6 levels in a Cox regression model the significance for the tocilizumab effect was lost (p<0.07). In this context, our observations evidence that optimal Covid-19 infection management with tocilizumab is not achieved during hyperglycemia both in diabetic and non-diabetic patients.
To calm inflammatory storm, tocilizumab was used for treating moderate-severe Covid-19 pneumonia by targeting IL-6 receptors (IL-6R) and reducing cytokine release (1). Despite the optimal management of Covid-19 infection including tocilizumab, the pooled rate ratio among diabetic patients with adverse vs those with the more favorable course was 2.26 (2). An important factor in any form of infection control in patients with diabetes seems to be the glucose control (2). Hyperglycemia has been shown to increaseIL-6 and IL-6R (3), which has been suggested as a severity predictor in lung diseases of Covid-19 patients (1). However, there are no data about the effects of tocilizumab therapy on outcomes of hyperglycemic Covid-19 patients with pneumonia. To investigate this unsolved need, 475 Covid-19 positive patients admitted to Infection Disease Departments (University of Bologna, University Vanvitelli Napoli, and San Sebastiano Caserta Hospital, Italy) since March 1st, 2020 were retrospectively studied. The study was approved by the Ethical Committee of The Institutional Review Boards. The patients and patients’ families signed informed consent to participate in the study. The diagnosis of COVID-19 was established according to World Health Organization interim guidance and confirmed by RNA detection of the SARS-CoV-2 in the microbiology laboratory of the hospitals. Among them, only 78patients with pneumonia disease and treated with tocilizumab were further evaluated for a severe outcome (encompassing both the use of mechanical ventilation and/or death). Thirty-one (39.7%) hyperglycemic and 47 (60.3%) normoglycemic Covid-19 positive patients (blood glucose levels ≥140 mg/dl, at admission and/or during hospital stay) were evaluated (4). Noteworthy, 20 (64%) of hyperglycemic and 11 (23.4%) of normoglycemic patients were also diabetics (P<0.01). Admission glucose levels were 187±48 vs 103+23 mg/dl (p<0.01) in hyperglycemic vs in normoglycemic patients. Along with the hospitalization, mean glucose levels were 157±15 vs 122 ±12 mg/dl (p<0.01) in hyperglycemic vs normoglycemic patients. At admission, more elevated IL-6 levels in hyperglycemic patients were found and persists even after Tocilizumab administration (Figure-A). In a risk adjusted Cox-regression analysis, Tocilizumab in hyperglycemic did not attenuate the risks of severe outcome as did in normoglycemic patients (p<0.009) (Figure-B).
The reduced effects of Tocilizumab in hyperglycemic patients may due to the higher plasma IL-6 levels. Previous study evidenced that tocilizumab efficacy was inversely proportional to the baseline IL-6 levels in patients with rheumatoid arthritis (5). Accordingly, our data evidence that hyperglycemic patients had IL-6 levels at admission 5-fold higher as compared to the normoglycemic patients. Interestingly, when we added IL-6 levels in a Cox regression model the significance for the tocilizumab effect was lost (p<0.07). In this context, our observations evidence that optimal Covid-19 infection management with tocilizumab is not achieved during hyperglycemia both in diabetic and non-diabetic patients. Thus, these data may be of interest for ongoing clinical trials on tocilizumab effects on Covid-19 patients and for the optimal control of glycemia in this subset.
Data Availability
Data are available.
Footnotes
Disclosure of all financial associations or other possible conflicts of interest for each author: None